Details of the Drug Reposition

General Information of This Drug (ID: DM6BZCV)

Drug Name
Sivelestat   DM6BZCV
Synonyms
127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
6 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple sclerosis DISB2WZI 8A40 Phase 3 [1]
Crohn disease DIS2C5Q8 DD70 Phase 3 [1]
Ulcerative colitis DIS8K27O DD71 Phase 3 [1]
Pyoderma gangrenosum DIS8QVTT EB21 Phase 3 [2]
Rheumatoid arthritis DISTSB4J FA20 Phase 3 [1]
Psoriatic arthritis DISLWTG2 FA21 Phase 3 [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)
2 Application submitted Indication(s)
Indication Name Indication ID ICD-11 Status REF
Anterior uveitis DISQ7EAD 9A96 Application submitted [3]
Axial spondyloarthritis DISBQOBN FA92.0 Application submitted [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)